On June 16, 2021 BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) reported that the Israeli Ministry of Health has accepted the regulatory submission of ORLADEYO for the prevention of recurrent attacks in patients with hereditary angioedema (HAE) 12 years and older(Press release, BioCryst Pharmaceuticals, JUN 16, 2021, View Source [SID1234584041]). The Israeli Ministry of Health also has granted an accelerated review. In addition, BioCryst has entered into a distribution and supply agreement granting Neopharm Ltd., a corporation organized under the laws of the State of Israel, the exclusive rights to commercialize ORLADEYO in Israel.
"Neopharm is the right partner to help us commercialize in Israel as we continue to bring oral, once-daily ORLADEYO to HAE patients around the world. They have extensive rare disease experience and proven commercial success in Israel, and they understand the local regulatory environment," said Charlie Gayer, chief commercial officer of BioCryst.
"We are proud of our partnership with BioCryst and excited to deliver a new and innovative treatment option to HAE patients in Israel. The momentum gained from recent approvals of ORLADEYO across the globe will support our commercialization efforts to provide access to this important treatment," said Efi Shnaidman, general manager of Neopharm Israel.
Founded in 1941, Neopharm Israel is one of the leading pharmaceutical companies in Israel, providing the Israeli market with a wide range of products and integrated services for patients in need, with a proven track record of successful market access and launches. In addition to exclusive rights to commercialize ORLADEYO in Israel, Neopharm Israel has exclusive rights to commercialize in the Palestinian Authority.